Scott Morgan

18PUBLICATIONS
50CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsChemotherapyRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 26, 2026
External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

|May 26, 2026
Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis.

|Jan 13, 2026
Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, Canada.

David-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari

|Dec 24, 2025
Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes.

Anna N Wilkinson, Larry F Ellison, Shary X Zhang

|Dec 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Georges Gebrael, Neeraj Agarwal, Alicia K Morgans

|Sep 04, 2025
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.

David-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari

Pageof 3

Frequent Collaborators

10 joint publications

Cristopher J D Wallis

9 joint publications

Soumyajit Roy

4 joint publications

Daniel E Spratt

4 joint publications

Shawn Malone